drugset / Trial / NCT00926965

Tardive Dyskinesia and Cognitive Function

NCT00926965

RandomizedParallel-groupSingle-blindTreatment

Summary

Previous researchers indicate that impaired cognitive flexibility was the primary factor distinguishing patients with from those without tardive dyskinesia (TD)1, and cognitive dysfunction correlates positively with the severity of TD2. Longitudinal data raised the possibility that the association between cognitive dysfunction and TD may reflect not organic vulnerability to but rather a state marker for this movement disorder as "tardive dementia"3. Atypical antipsychotic had been reported to alleviate the severity of TD4 and improved neurocognitive function separately5. But no researchers ever investigated the correlation of the two effects simultaneously. This randomized, single-blind and controlled study compared the effect of atypical antipsychotic on TD, neurocognitive function and associated factors for these changes.

Timeline

Start
2003-01
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule 100 mg
Subject Amisulpride Small molecule 800 mg
Subject Amisulpride Small molecule 1200 mg
Subject Olanzapine Small molecule 2.5 mg
Subject Olanzapine Small molecule 30 mg